Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enlivex Ltd. - Ordinary Shares (NQ:ENLV)

1.175 +0.135 (+12.98%)
Streaming Delayed Price Updated: 10:48 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enlivex Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance
Via ACCESS Newswire
News headline image
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Kartoon Studios Mainframe Studios, Toon Media, and Premium IP Pipeline Drive 2026-2027 Outlook
Via AB Newswire
News headline image
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Selected to Present at Israeli BioMed 2025 Conference
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis
Via ACCESS Newswire
News headline image
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.